Recurrent Pericarditis (RP) is a painful auto-inflammatory cardiovascular disease that occurs when patients with acute pericarditis experience one or...
Often when pharmacy benefit manager (PBM) agreements and specialty pharmacy agreements are put into place, no one considers the 1 or 2 percent of the...
Orsini Specialty Pharmacy, a leading independent specialty pharmacy focused on rare diseases and gene therapies, announced that Krystal Biotech has...
Whether it's open, limited, or exclusive, the main goal of all healthcare distribution network systems should be to provide patients access to the...
Traditional specialty drugs for diseases such as rheumatoid arthritis and multiple sclerosis are best served under an open distribution model where...
Before any anticipated specialty drug launch, a pharmaceutical manufacturer conducts an extensive market access evaluation to determine the best...
On Rare Disease Day, we are dedicating this blog to Tommy, a selfless and caring individual we had the opportunity to serve for several years. In 2003,...
Orsini Specialty Pharmacy, a leading independent specialty pharmacy focused on rare diseases and gene therapies, has earned URAC’s prestigious...
According to the National Institutes of Health (NIH), approximately 7,000 rare diseases affect between 25 and 30 million Americans (almost 1 in 10)1....
Almost 1 in 10 Americans are affected by a rare disease.1 Common challenges rare disease patients face include limited treatment options, little to no...
Orsini is a leading independent national specialty pharmacy accredited by ACHC, JCAHO, URAC, and VIPPS. The services we provide allow patients, physicians, payors, and manufacturers to improve care, simplify processes, and achieve better outcomes.
Orsini selected as the exclusive specialty pharmacy for WAINUA (eplontersen) for adults with hereditary transthyretin-mediated amyloid polyneuropathy
Now In Stock: ADZYNMA (ADAMTS13, recombinant-krhn), for patients with cTTP
Orsini Specialty Pharmacy Selected as Distribution Partner for Adzynma (ADAMTS13, recombinant-krhn), a Newly Approved Treatment for an Ultra-Rare Blood Clotting Disorder
Orsini Specialty Pharmacy Partners with Amicus Therapeutics to Dispense New Therapy for the Treatment of Late-Onset Pompe Disease
Orsini Specialty Pharmacy Names Darin DeCarlo Chief Growth Officer